Feature
Article
Pharmaceutical Executive
How AI is Shaping KOL and DOL Identification
Author(s):
Key Takeaways
- The pharmaceutical industry must balance traditional KOLs and emerging DOLs to effectively engage healthcare professionals as thought leaders.
- AI-driven systems enhance influencer identification by integrating structured and unstructured data, offering dynamic and objective assessments.
As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.
Global Reference Info & Digital, IQVIA
The pharmaceutical industry stands at a critical inflection point in how it identifies and engages healthcare professionals (HCPs) as thought leaders. As traditional key opinion leaders (KOLs) continue to shape scientific discourse, digital opinion leaders (DOLs) have emerged to leverage social media and online platforms for broader reach. The challenge lies in accurately identifying leaders with genuine influence in an increasingly complex digital landscape.
The combination of comprehensive HCP data, advanced matching capabilities, and artificial intelligence’s (AI’s) ability to process vast volumes of unstructured information is transforming the identification process. This integrated approach offers unprecedented precision, real-time adaptability and objective assessment capabilities.
The evolving landscape of healthcare influence
The distinction between KOLs and DOLs reflects fundamentally different approaches to building influence. KOLs establish authority through scientific contributions—peer-reviewed publications, clinical trial leadership, and research credentials. Their influence operates within traditional academic channels where domain expertise carries significant weight.
DOLs build influence through active digital engagement, translating complex medical information into accessible content and fostering online communities. They excel at synthesizing and communicating complex medical information, creating valuable bridges between scientific discovery and practical application for broader healthcare audiences.
The pharmaceutical industry increasingly recognizes both types as essential.
KOLs primarily provide scientific credibility within specific therapeutic areas, while DOLs usually offer broader reach and real-time responsiveness.
This complementary relationship means successful strategies must account for both traditional scientific influence and modern digital broadcasting capabilities. The lines continue to blur as established KOLs leverage digital channels while influential DOLs develop deeper scientific expertise.
The limitations of traditional ID methods
Traditional approaches rely heavily on subjective assessments and manually compiled data that quickly become outdated. These methods typically focus on easily quantifiable metrics like publication counts or conference presentations, which provide incomplete pictures of actual influence.
Such approaches often miss emerging voices who haven’t yet accumulated traditional credentials but may be driving important conversations in digital spaces.
More fundamentally, the static nature of traditional identification creates significant blind spots. Healthcare influence, particularly in digital environments, shifts rapidly based on current events, breakthrough research, and trending therapeutic discussions. An assessment conducted even three months ago may no longer reflect a professional’s current relevance or engagement levels, leading to missed opportunities with newly influential voices or continued outreach to professionals whose influence has waned.
Resource intensity compounds these challenges. Manual identification processes demand substantial time and expertise to research individual professionals, verify credentials, and map influence networks. This becomes particularly problematic when scaling across multiple therapeutic areas or attempting to identify DOLs whose influence exists primarily in social media environments that resist systematic manual monitoring.
Perhaps most critically, traditional methods struggle with the identity verification challenges inherent in digital platforms. Social media profiles frequently use abbreviated names, professional pseudonyms or incomplete biographical information, making it difficult to confirm that online activity represents qualified HCPs instead of individuals falsely claiming medical expertise.
How AI transforms influencer identification
By analyzing data sets far beyond human processing capacity, AI can transform how identification is made. These systems simultaneously evaluate traditional scientific metrics alongside digital engagement patterns, social network analysis, and real-time conversation monitoring. This multidimensional approach identifies HPCs based on actual influence rather than proxy measures such as publication volume alone.
Technology’s strength lies in connecting structured data—publication records, clinical trial involvement, institutional affiliations—with unstructured digital content from social platforms, blogs, and online forums. This integration enables accurate identification of individuals across their various professional activities, revealing complete influence profiles that span both traditional and digital channels.
Unlike static traditional assessments, AI systems continuously monitor conversations, track engagement metrics, and update influence scores based on current activity. A clinician who publishes infrequently but generates significant discussion around emerging treatments might be missed by traditional methods yet identified immediately by AI monitoring systems.
This dynamic tracking ensures identification reflects present-day influence instead of outdated snapshots.
Perhaps most important, AI-driven assessment eliminates subjective biases that often skew manual identification. By focusing on measurable engagement metrics, network connections and content impact, these systems can provide consistent, objective results.
This proves especially valuable for DOL assessment, where influence patterns may diverge significantly from traditional academic hierarchies.
Advanced implementations demonstrate these capabilities by processing millions of daily touchpoints while maintaining accurate professional verification. These systems distinguish legitimate HCPs from individuals falsely claiming medical expertise—a critical quality control measure in digital spaces, where credentials aren’t always transparent. The result enables pharmaceutical teams to focus engagement efforts on verified professionals actively discussing relevant therapeutic areas.1
Implementation strategies
Successful integration ofAI-driven identification into launch planning requires strategic alignment between technology capabilities and business objectives. Companies should first define clear goals—whether prioritizing scientific validation through established researchers, building broader market awareness via digital channel, or penetrating specific therapeutic communities. These objectives directly influence which types of leaders to target and how to structure subsequent engagement approaches.
The sophistication of modern AI systems also creates new opportunities for precision targeting. Rather than broad-based outreach, companies can identify professionals who demonstrate genuine expertise in narrow therapeutic areas or specific treatment modalities.
This granular identification enables more personalized engagement strategies that resonate with individual interests and specializations.
However, effective implementation requires careful attention to data transparency and compliance. Marketing teams must understand not only who has been identified but also how that identification occurred, particularly when engaging individuals whose influence stems primarily from digital activities. This understanding proves essential for maintaining appropriate engagement boundaries and ensuring all interactions feel natural instead of overly informed by data mining.
Despite AI’s analytical power, human oversight remains indispensable for successful implementation. Technology excels at identifying patterns and flagging potential influencers, but experienced professionals must validate results, interpret nuanced cases, and shape engagement strategies. This is particularly critical when considering regional variations. Each market has unique cultural contexts and digital behaviors that influence how HCPs engage online.
For instance, preferred platforms, communication styles, and even the pace of digital adoption vary significantly across geographies. The most effective programs combine AI’s processing capabilities with local market expertise and therapeutic area knowledge, creating approaches that respect both data-driven insights and important cultural factors.
The strategic imperative for AI-driven influence mapping
The strategic imperative for comprehensive influence mapping has never been clearer. As pharma companies navigate an increasingly complex landscape of scientific and digital influence, the ability to accurately identify and understand both KOLs and DOLs becomes essential for effective engagement. By leveraging advanced identification capabilities, companies can move beyond surface-level metrics to understand who truly shapes therapeutic conversations, how influence networks interconnect, and which voices carry weight in specific treatment areas.
This deeper understanding enables more precise communication strategies—tailoring messages to resonate with individual influencers’ interests, preferred channels and areas of expertise. Companies that excel at mapping these influence networks gain the ability to engage the right professionals at the right time with the right content, ultimately improving how new treatments reach the patients who need them.
Esther Van Hulten is VP and GM, Global Reference Info & Digital, at IQVIA
Reference
1. Rise of Digital Opinion Leaders: Transforming the Influence Landscape in Life Sciences and Medtech. IQVIA Insight Brief. August 30, 2023. https://www.iqvia.com/library/white-papers/transforming-the-influence-landscape-in-life-sciences-and-medtech
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
